Navigation Links
Vidaza receives positve opinion from European CHMP
Date:10/27/2008

The Aplastic Anemia & MDS International Foundation is pleased to inform patients that the European Committee for Medicinal Products for Human Use (CHMP) has awarded Vidaza (azacitidine) a positive opinion for the treatment of myelodysplastic syndromes (MDS) patients who are not eligible for stem cell transplants.

The CHMP's positive opinion is based on data from the AZA-001 trial, which demonstrated an overall, unprecedented survival benefit for higher-risk MDS patients. The positive opinion will be forwarded to the European Commission that generally follows the recommendation of the CHMP and issues final marketing approval.

"We are excited by Vidaza's positive CHMP opinion because there are few treatment options for patients in Europe with this disease," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation, "Vidaza not only extends patients' lives, but also improves their quality of life. We are hopeful that Vidaza will receive marketing approval shortly and quickly be available for patients across Europe."

Myelodysplastic syndromes (MDS) occur when the bone marrow stem cells malfunction. This results in the production of too many defective blood cells and not enough normal cells. Diagnosis is made through blood tests and a bone marrow biopsy. Once diagnosed, treatment and evaluation should occur under the care of a hematologist or hematologists/oncologist. There are many subtypes of MDS classified according to how the disease manifests itself in the blood and marrow of the patient. Treatments include blood transfusions, growth factors, chemotherapy and bone marrow transplant.


'/>"/>

Contact: John Huber
huber@aamds.org
301-279-7202
Aplastic Anemia & MDS International Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
2. FDA approves Vidaza label expansion
3. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
4. Penn State receives new NASA astrobiology grant
5. American College of Medical Genetics receives $13.5M NIH contract
6. Kount Receives Patent for Device Fingerprinting
7. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
8. Wistar Institute researcher receives New Innovator award from NIH
9. CCNY receives $5 million NSF grant to establish center for nanostructure applications
10. NYU receives $490k NSF grant to promote women in the sciences
11. Childrens National researcher receives ACCP Distinguished Investigator Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 30, 2014  Aware, Inc. (NASDAQ: AWRE ... previously announced on June 26, 2014 that its Board ... $1.75 per share, or approximately $40 million in total.  ... 2014 and a payment date of July 24, 2014.  ... had set an ex-dividend date for this special cash ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... 3, 2014 Research and Markets ( ... "Global Gesture Recognition & Touch-Less Sensing (2D, ... 2020" report to their offering ... Recognition & Touch-Less Sensing Market to Grow Exponentially. ... while, but the companies were unable to leverage ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... NJ, March 20, 2013, John Wiley & Sons, Inc., ... Society (SPPS); a partnership which began over sixty years ... research journal Physiologia Plantarum , an international thought ... partnership began in 1948 when the society, known then ...
... uncovered from poorly explored areas of the Peruvian jungles. The ... before a dark brown and black background. It is assumed ... a slight difference in altitude ranges, which makes their biological ... was published in the open access journal Zookeys ...
... of the natural motors that are serving as models for ... therapeutic DNA, RNA or drugs into individual diseased cells. Their ... bacteria-killing virus and a new way to move DNA ... journal ACS Nano . Peixuan Guo and colleagues ...
Cached Biology News:The Scandinavian Plant Physiology Society and Wiley extend over 60 years of partnership 2Peru surprises with 2 new amazing species of woodlizards 2
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... According to the International Atomic Energy Agency (IAEA) ... terrorists acquiring sufficient quantities of plutonium or highly ... explosive device. The IAEA also notes that most ... quantities, which can be challenging to detect with ... study appearing this week in the Journal ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
Breaking Biology Technology:Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2
... , RESEARCH TRIANGLE PARK, N.C. , May 4 ... therapeutics, announced today that Kenneth I. Moch has ... Chimerix as Chief Operating Officer in July 2009 , ... and financing biomedical companies.  Mr. Moch will also join the ...
... May 4 PharmAthene, Inc. (NYSE Amex: PIP ), ... today announced that the Company,s Interim CEO, Eric I. Richman ... the critical interrelationship between government, academia and industry in the development ... , , ...
... Packing Record Tetrahedral dice, which have four ... yet tested, according to research performed by a collaboration ... revelation is the result of a series of experiments ... and adding more dice until the containers were completely ...
Cached Biology Technology:Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 2Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 3Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 4PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference 2Densest dice packing and computing with molecules 2
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... component of the COP9 signalosome complex (CSN), ... developmental processes. The CSN complex is an ... pathway by mediating the deneddylation of the ... The complex is also involved in phosphorylation ...
... STAR3000 HISTAR detection systems provide linking ... used with species specific primary antibodies ... specimens. Visualisation is accomplished using an ... novel polymer labelling technology. Secondary antibodies ...
Biology Products: